Experts discuss a 3D co-culture platform for the propagation of primary multiple myeloma cells ex vivo.
Understanding preclinical modeling for cancer cells may optimize the translation of in vitro findings into clinical use, but is limited by the inability to reproducibly propagate primary specimens ex vivo. This dilemma is seen in multiple myeloma, a plasma cell disorder for which treatment significantly improved over the past several decades. Cell line models for multiple myeloma remain inefficient in predicting later clinical efficacy and the failure rate of preclinically promising anti-cancer drugs remains substantial. During this webinar, Johannes Waldschmidt, MD, and Andreas Thomsen, MD, of the University of Freiburg in Germany, will discuss a 3D co-culture platform for the propagation of primary multiple myeloma cells ex vivo.
Presenters

Johannes Waldschmidt
Johannes Waldschmidt, MD, studied medicine at the University of Freiburg, Germany; the University of Uppsala, Sweden; and the University of Zurich, Switzerland. He was trained as a hematologist-oncologist at Freiburg University Medical Center, where his experimental work has focused on characterizing the bone marrow microenvironment in multiple myeloma. As postdoctoral fellow in the lab of Jens Lohr, MD, PhD, at the Dana-Farber Cancer Institute in Boston, Waldschmidt studied cancer genomics, clonal evolution and the development of drug resistance in multiple myeloma. He is a recipient of the 2019 Young Investigator Award by the International Myeloma Society.

Andreas Thomsen
Andreas Thomsen, MD, is a radiation oncology specialist in the Department of Radiation Oncology at the University Medical Center Freiburg in Germany. For more than 20 years, he has been active in the field of 3D cell culture and tissue engineering, having worked in two biotech companies before moving into clinical and experimental radiation oncology. Thomsen’s research interest is on 3D tissue and cell culture models for radiation biology. He has developed a hydrogel array of conical microcavities for generation and screening of 3D cell aggregates.

Marco Leu
Marco Leu, PhD, MBA, is the co-founder and chief operating officer of abc biopply, a contract research organization based in Switzerland that has pioneered a portfolio of 3D tissue imaging and analysis assays. Abc Biopply’s techniques are based on the innovative flexibility of their 3D CoSeedis™ Co-Culture System, which enables the generation of quantitative datasets from tissues and cells.
Sponsor

abc biopply
Content Partners

American Physiological Society
About APS
Mission: To advance scientific discovery, understand life, and improve health. Vision: A global multidisciplinary community of scientists solving the major problems affecting life and health. Founded in 1887, the American Physiological Society is a global leader in expanding knowledge related to biological function. We connect a multidisciplinary community of nearly 10,000 scientists and educators from around the world, driving collaboration and spotlighting scientific discoveries in physiology and related disciplines. Our members are advancing treatments and cures for everything from cancer and heart disease, to obesity and addiction. They are also deepening our insight into living organisms generally, helping us to better understand how things like climate change are affecting the world around us. The Society serves this dynamic community in many ways, including:- Publishing 16 globally recognized scholarly journals and a highly-regarded book monograph series;
- Sponsoring scientific meetings and symposia that explore the frontiers of bio-medical science;
- Advocating for science-smart public policy that benefits both our members and the public;
- Bestowing hundreds of awards, grants, and fellowships that recognize scientific excellence and promise;
- Championing physiology education and educators, to support bigger discoveries and better clinical outcomes;
- And providing career resources and other career services, ensuring that all our members have a pathway to success.


































































































